| 0.022 0.001 (4.76%) | 02-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.03 | 1-year : | 0.03 |
| Resists | First : | 0.02 | Second : | 0.02 |
| Pivot price | 0.02 |
|||
| Supports | First : | 0.01 | Second : | 0.01 |
| MAs | MA(5) : | 0.02 |
MA(20) : | 0.02  |
| MA(100) : | 0.02 |
MA(250) : | 0.02 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 34.1 |
D(3) : | 26.3 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 0.05 | Low : | 0.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GRTX ] has closed below upper band by 30.4%. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.02 - 0.02 | 0.02 - 0.02 |
| Low: | 0.02 - 0.02 | 0.02 - 0.02 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Wed, 22 Oct 2025
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Wed, 22 Oct 2025
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Mon, 31 Mar 2025
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Thu, 02 Jan 2025
Galera Therapeutics Acquires Nova Pharmaceuticals to Advance Breast Cancer Treatment - MyChesCo
Tue, 31 Dec 2024
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - GlobeNewswire
Tue, 31 Dec 2024
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 36.2 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 2,120 (K) |
| Shares Short P.Month | 2,660 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|